On Tuesday, Inozyme Pharma Inc (NASDAQ: INZY) opened lower -2.66% from the last session, before settling in for the closing price of $3.01. Price fluctuations for INZY have ranged from $2.38 to $7.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -16.72% at the time writing. With a float of $43.99 million, this company’s outstanding shares have now reached $64.18 million.
The firm has a total of 59 workers. Let’s measure their productivity. In terms of profitability, gross margin is 55.92%, operating margin of -5043.98%, and the pretax margin is -4883.3%.
Inozyme Pharma Inc (INZY) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Inozyme Pharma Inc is 31.52%, while institutional ownership is 65.07%. The most recent insider transaction that took place on Apr 02 ’24, was worth 52,210. In this transaction CEO of this company sold 7,523 shares at a rate of $6.94, taking the stock ownership to the 20,665 shares.
Inozyme Pharma Inc (INZY) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -16.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.10% during the next five years compared to -35.73% drop over the previous five years of trading.
Inozyme Pharma Inc (NASDAQ: INZY) Trading Performance Indicators
Check out the current performance indicators for Inozyme Pharma Inc (INZY). In the past quarter, the stock posted a quick ratio of 7.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Inozyme Pharma Inc (INZY)
Analysing the last 5-days average volume posted by the [Inozyme Pharma Inc, INZY], we can find that recorded value of 0.51 million was better than the volume posted last year of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 40.33%. Additionally, its Average True Range was 0.25.
During the past 100 days, Inozyme Pharma Inc’s (INZY) raw stochastic average was set at 14.14%, which indicates a significant decrease from 50.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.08% in the past 14 days, which was higher than the 62.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.61, while its 200-day Moving Average is $4.75. Now, the first resistance to watch is $3.00. This is followed by the second major resistance level at $3.07. The third major resistance level sits at $3.14. If the price goes on to break the first support level at $2.86, it is likely to go to the next support level at $2.79. Now, if the price goes above the second support level, the third support stands at $2.72.
Inozyme Pharma Inc (NASDAQ: INZY) Key Stats
There are currently 64,240K shares outstanding in the company with a market cap of 188.22 million. Presently, the company’s annual sales total 0 K according to its annual income of -71,170 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -24,570 K.
